TICKERNERD
Menu
ACBACBHealthcare · Drug Manufacturers - Specialty & Generic

ACB Stock Forecast: Aurora Cannabis, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.74
+0.27% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$236.8M
Ticker Nerd rank
48 / 100
Median analyst target
—
Analysts covering
5
Revenue$67.6M−31.1% y/y
Operating income−$8.7M
Net income−$4.0M
Free cash flow−$9.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
+7.3%
YTD
−11.4%
1Y
−24.1%
From 52W high
−40.0%
From 52W low
+45.0%
$2.58
$6.23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aurora Cannabis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
78
Accruals
76
Issuance
71
Size
65
Quality
45
Volatility
30
Momentum
29
Value
25
Growth
18

Revisions (78): Analysts have, on balance, been raising their forecasts.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26ACB

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
2 Buy3 Hold0 Sell
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
27 June 2024Zuanic & AssociatesInitiatesNeutral—
16 June 2023CIBCMaintainsNeutral$1.75 → $1.00
15 June 2023Canaccord GenuityMaintainsHold$1.50 → $0.80
13 Feb 2023CIBCMaintainsNeutral$2.25 → $1.75
21 Sept 2022Piper SandlerMaintainsNeutral$4.00 → $3.00
28 Sept 2021MKM PartnersUpgradeNeutral—
18 Dec 2020BMO CapitalDowngradeUnderperform$9.00
25 Nov 2020B of A SecuritiesDowngradeNeutral—
25 Nov 2020Bank of AmericaDowngradeNeutral—
25 Nov 2020Cowen & Co.InitiatesOutperform—
25 Nov 2020DesjardinsInitiatesBuy—
25 Nov 2020JefferiesInitiatesBuy—
25 Nov 2020Ladenburg ThalmannDowngradeNeutral—
25 Nov 2020MKM PartnersInitiatesSell—
25 Nov 2020NeedhamInitiatesHold—
25 Nov 2020Piper JaffrayMaintainsNeutral—
25 Nov 2020Piper SandlerMaintainsNeutral—
25 Nov 2020Seaport GlobalInitiatesNeutral—
25 Nov 2020StifelDowngradeSell—
25 Nov 2020Stifel NicolausInitiatesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Aurora Cannabis, Inc. returned −24.1% against +17.5% for the S&P 500, dividends included.

ACB vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26ACBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Aurora Cannabis, Inc. (ACB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
20.8×

Cheaper than 36% of US stocks

Price / sales
0.8×

Cheaper than 75% of US stocks

Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
−5.5×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
−8.8%

Higher than 17% of US stocks

Earnings growth (YoY)
−31.1%

Higher than 15% of US stocks

Gross margin
52.7%

Higher than 65% of US stocks

Operating margin
−12.9%

Higher than 23% of US stocks

Net margin
−38.3%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−9.4%

Higher than 36% of US stocks

Return on assets
−3.7%

Higher than 34% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aurora Cannabis, Inc. (ACB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aurora Cannabis, Inc. has a market value of $236.8M and an enterprise value of $119.1M.

  • Revenue in the twelve months to 30 June 2026: $290.1M. The latest quarter shrank 8.8% year on year.

  • Net income over the same four quarters: −$120.1M, a −41.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$51.2M.

  • Shares outstanding: 63.3M.

  • Trailing P/E: 20.8×; forward P/E: −34.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Aurora Cannabis, Inc. employs 1,028 people — $282K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ACB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ACBAurora Cannabis, Inc.$236.8M
48
CRDLCardiol Therapeutics, Inc.$233.1M
61
AKBAAkebia Therapeutics, Inc.$254.9M
78
SIGASIGA Technologies, Inc.$217.1M
41
ANIKAnika Therapeutics, Inc.$279.5M
100
DERMJourney Medical Corp.$197.6M
65
ORGOOrganogenesis Holdings, Inc.$189.1M
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aurora Cannabis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACB news & analysis

$250,000 in These 3 High-Income ETFs Could Pay You ~$2,800 a Month

24/7 Wall Street · 11 Sept 2026neutral

The article highlights that options-income ETFs deliver much higher monthly payouts than traditional dividend stocks, framing a $250,000 investment in three such funds as potentially yielding roughly $2,800 a month. It cautions that investors often overlook tax mechanics and capital preservation risks before moving their money.

Why it matters — An ACB watcher would care because it draws attention to alternative high-income investment vehicles that compete with and may redirect retail investors' capital away from dividend-paying stocks like Aurora Cannabis.

Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business

PRNewsWire · 9 Sept 2026positive

Aurora Cannabis announced that Faris El Refaie, a biopharmaceutical executive with 25 years of experience, will join the company as Executive Vice President, Global Commercial, effective September 28, 2026. He will lead commercial acceleration of the company's global medical cannabis business.

Why it matters — ACB watchers would care because the appointment of a seasoned biopharmaceutical executive to lead global commercial operations signals a strategic focus on strengthening the company's medical cannabis business.

Aurora Cannabis Calls Curaleaf Offer Inadequate, Urges Rejection

WSJ · 2 Sept 2026negative

Aurora Cannabis is urging its shareholders to reject an unsolicited $272 million hostile takeover bid from Curaleaf Holdings, calling the offer inadequate. The company is publicly opposing the bid and recommending shareholders vote against it.

Why it matters — The hostile bid and Aurora's rejection effort represent a significant corporate-control struggle that could determine the company's ownership and future direction.

Aurora Cannabis Urges Shareholders to REJECT Curaleaf's Hostile Bid, Warning that it is Inadequate, Undervalues Aurora and Puts Shareholder Value and Future Upside at Risk

PRNewsWire · 2 Sept 2026negative

Aurora Cannabis issued a directors' circular urging shareholders to reject Curaleaf's unsolicited hostile takeover bid, arguing that the offer undervalues Aurora, exposes shareholders to risks, and could weaken shareholder rights. Aurora says the bid aims to capture its assets at a discount while the company is debt-free with $149 million in cash, compared to Curaleaf's over $1 billion in debt.

Why it matters — This item matters to ACB watchers because it directly involves a hostile takeover attempt that could determine the company's future ownership, valuation, and shareholder protections, making Aurora's board's rejection stance a key development to monitor.

Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid?

The Motley Fool · 28 Aug 2026negative

Curaleaf has launched a hostile takeover bid for Aurora Cannabis, offering Aurora shareholders $4 per share. Aurora maintains that the hostile bid undervalues the company.

Why it matters — The hostile takeover bid could materially affect Aurora's future direction and the value received by its shareholders.

FAQ

Frequently asked questions about ACB stock

Is ACB stock a buy right now?

Of the 5 analysts covering Aurora Cannabis, Inc., 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aurora Cannabis, Inc. 48 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACB?

As at 12 Sept 2026, Aurora Cannabis, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (78 of 100).

What is the ACB stock forecast for 2030?

No analyst covering Aurora Cannabis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACB are extrapolating price history, which says nothing about the business.

How has ACB stock performed over the past year?

Aurora Cannabis, Inc. returned -24.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aurora Cannabis, Inc. do?

Aurora Cannabis Inc. is a Canadian cannabis company focused on the production, distribution, and sale of cannabis and cannabis-derived products in Canada and international markets.

What is the latest news on ACB?

The most recent item we track (24/7 Wall Street, 11 Sept 2026): "$250,000 in These 3 High-Income ETFs Could Pay You ~$2,800 a Month". The article highlights that options-income ETFs deliver much higher monthly payouts than traditional dividend stocks, framing a $250,000 investment in three such funds as potentially yielding roughly $2,800 a month. It cautions that investors often overlook tax mechanics and capital preservation risks before moving their money.

Company

About Aurora Cannabis, Inc.

Aurora Cannabis Inc. is a Canadian cannabis company focused on the production, distribution, and sale of cannabis and cannabis-derived products in Canada and international markets. Aurora Cannabis Inc. serves both medical and consumer segments with offerings that include pharmaceutical-grade cannabis, dried flower, oils, capsules, concentrates, and other product formats designed for adult-use and therapeutic applications. The company operates through cannabis and plant propagation businesses, supporting a portfolio that spans branded consumer products, medical cannabis channels, and agricultural propagation activities. Headquartered in Edmonton, Alberta, Aurora Cannabis Inc. plays a notable role in the regulated cannabis industry by supplying patients, consumers, and wholesale partners across multiple regions.

CEO Mr. Miguel Martin · 1,028 employees · Canada · https://www.auroramj.com